Ladapo Asks CDC to Look Into Myocarditis in Young Boys After COVID Vaccination

Published Aug. 18, 2022, 1:46 p.m. ET | Updated Aug. 18, 2022

Dr Joseph Ladapo Interview_Moment

August 18, 2022 Updated 1:46 P.M. ET

TALLAHSSEE (FLV) – Florida Surgeon General Joseph Ladapo highlighted a pre-print from Thailand which reportedly found that 3.5% of adolescent boys receiving a second dose of the COVID-19 vaccine had “overt or subclinical myocarditis,” inflammation of the heart muscle.

“A pre-print from Thailand found that 3.5% of adolescent boys had overt or subclinical myocarditis after getting the second dose of the COVID-19 vaccine. Is @CDCGov doing similar prospective study in the US? Is anyone?” the Surgeon General questioned on Twitter.

A breakdown of the study from Vinay Prasad, an associate professor on various medical subfields, slams policymakers and leaders for ignoring suggestions of remedying risks of myocarditis via lower dosages, single dosages, exemptions, restrictions, setting higher bars for boosters for men, and more.

“Instead of taking any of these actions, which we suggested at the time, the public health community downplayed, gaslighted and mislead about the concern,” he wrote.

Current COVID vaccine guidance from the State of Florida warns against young people, particularly young boys, from receiving a COVID vaccination because the risks may outweigh the benefits.

“Based on currently available data, healthy children aged 5 to 17 may not benefit from receiving the currently available COVID-19 vaccine,” it says.

The Department lists multiple factors that “may” cause risks to outweigh benefits of the vaccine, including their already low risk of severe illness to COVID-19, high prevalence of immunity in children, absence of data supporting vaccination benefit on children with immunity, higher than anticipated adverse events in vaccine recipients, reduced efficacy in children 5-17, and the risk of myocarditis (heart inflammation) due to the vaccine.

It notes that children with underlying health conditions or comorbidities should be considered with their doctor.

“In general, healthy children with no significant underlying health conditions under 16 years old are at little to no risk of severe illness complications from COVID-19.”

They note that in children aged 16 to 17, the risk of myocarditis may outweigh the benefits.

One study found that the efficacy of the vaccine fell 40% over two months in children aged 12 to 17.

Another study also found the highest rates of myocarditis among males aged 12 to 15, followed by those aged 16 to 17.

For the full health guidance and links to clinical data, click here.

Share This Post

Latest News

0 0 votes
Article Rating
Subscribe
Notify of
guest

1 Comment
Oldest
Newest Most Voted
Inline Feedbacks
View all comments